Development and validation of an artificial intelligence PIVKA-II-based model for the prediction of hepatocellular carcinoma development in patients with HCV-related cirrhosis successfully treated with direct-acting antivirals

被引：0
|
作者：
Caviglia, G. P. [1 ]
Fariselli, P. [2 ]
D'Ambrosio, R. [3 ]
Degasperi, E. [3 ]
Troshina, G. [1 ]
Nicolosi, A. [1 ]
Saracco, G. M. [1 ,4 ]
Lampertico, P. [3 ,5 ]
Ciancio, A. [1 ,4 ]
机构：
[1] Univ Turin, Dept Med Sci, Liver Unit, Turin, Italy
[2] Univ Turin, Dept Med Sci, Computat Biomed, Turin, Italy
[3] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Milan, Italy
[4] Citta Salute & Sci Torino Molinette Hosp, Gastroenterol Unit, Turin, Italy
[5] Univ Milan, Dept Pathophysiol & Transplantat, CRC AM & Migliavacca Ctr Liver Dis, Milan, Italy
来源：
DIGESTIVE AND LIVER DISEASE | 2022年 / 54卷
关键词：
D O I：
10.1016/j.dld.2022.08.002
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OC-01
引用
收藏
页码：S165 / S165
页数：1
相关论文
共 50 条
  • [1] Development and Validation of a PIVKA-II-Based Model for HCC Risk Stratification in Patients With HCV-Related Cirrhosis Successfully Treated With DAA
    Caviglia, Gian Paolo
    Fariselli, Piero
    D'Ambrosio, Roberta
    Colombatto, Piero
    Degasperi, Elisabetta
    Ricco, Gabriele
    Abate, Maria Lorena
    Birolo, Giovanni
    Troshina, Giulia
    Damone, Francesco
    Coco, Barbara
    Cavallone, Daniela
    Perbellini, Riccardo
    Monico, Sara
    Saracco, Giorgio Maria
    Brunetto, Maurizia Rossana
    Lampertico, Pietro
    Ciancio, Alessia
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, 61 (03) : 538 - 549
  • [2] Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals
    Conti, Fabio
    Buonfiglioli, Federica
    Scuteri, Alessandra
    Crespi, Cristina
    Bolondi, Luigi
    Caraceni, Paolo
    Foschi, Francesco Giuseppe
    Lenzi, Marco
    Mazzella, Giuseppe
    Verucchi, Gabriella
    Andreone, Pietro
    Brillanti, Stefano
    JOURNAL OF HEPATOLOGY, 2016, 65 (04) : 727 - 733
  • [3] PIVKA II a useful biomarker for hepatocellular carcinoma in caucasian HCV cirrhotic patients treated with direct-acting antivirals
    Degasperi, E.
    De Monti, A.
    Perbellini, R.
    D'Ambrosio, R.
    Lunghi, G.
    Ceriotti, F.
    Perego, A.
    Orsini, C.
    Borghi, M.
    Iavarone, M.
    Bruccoleri, M.
    Sangiovanni, A.
    Lampertico, P.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : E10 - E11
  • [4] Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals
    Caviglia, Gian Paolo
    Troshina, Giulia
    Santaniello, Umberto
    Rosati, Giulia
    Bombaci, Francesco
    Birolo, Giovanni
    Nicolosi, Aurora
    Saracco, Giorgio Maria
    Ciancio, Alessia
    CANCERS, 2022, 14 (03)
  • [5] RISK OF HEPATOCELLULAR CARCINOMA IN HCV-RELATED CIRRHOSIS TREATED WITH DIRECT-ACTING ANTIVIRAL (DAA) THERAPY
    Kilany, Shimaa
    Gomaa, Asmaa Ibrahim
    Sabry, Alyaa
    Moaz, Inas
    Ezzat, Sameera
    Badra, Gamal Ahmed
    Waked, Imam
    HEPATOLOGY, 2019, 70 : 321A - 322A
  • [6] PIVKA-II LEVELS PREDICT HEPATOCELLULAR CARCINOMA DEVELOPMENT AND IMPROVE THE DIAGNOSTIC ACCURACY FOR HCC IN CAUCASIAN HCV CIRRHOTIC PATIENTS TREATED WITH DIRECT-ACTING ANTIVIRALS
    Degasperi, Elisabetta
    De Monti, Alberta
    Perbellini, Riccardo
    D'Ambrosio, Roberta
    Lunghi, Giovanna
    Ceriotti, Ferruccio
    Perego, Alberto
    Borghi, Marta
    Iavarone, Massimo
    Bruccoleri, Mariangela
    Sangiovanni, Angelo
    Lampertico, Pietro
    HEPATOLOGY, 2019, 70 : 237A - 238A
  • [7] DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN HCV CIRRHOTIC PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS
    Buonfiglioli, F.
    Conti, F.
    Andreone, P.
    Crespi, C.
    Foschi, F. G.
    Lenzi, M.
    Mazzella, G.
    Verucchi, G.
    Brillanti, S.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S215 - S215
  • [8] PREDICTION OF HEPATOCELLULAR CARCINOMA DEVELOPMENT IN KOREAN PATIENTS WHO WERE TREATED WITH DIRECT-ACTING ANTIVIRALS
    Hong, Hyeyeon
    Choi, Jonggi
    Jeon, Dongsub
    Choi, Won-Mook
    Lee, Danbi
    Shim, Ju Hyun
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    HEPATOLOGY, 2022, 76 : S355 - S355
  • [9] Immune inflammation indicators and ALBI score to predict occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals
    Gardini, A. C.
    Foschi, F. G.
    Conti, F.
    Petracci, E.
    Marisi, G.
    Buonfiglioli, F.
    Ravaioli, M.
    Mazzella, G.
    Muratori, P.
    Lenzi, M.
    Crespi, C.
    Bolondi, L.
    Badia, L.
    Verucchi, G.
    Vitale, G.
    Vukotic, R.
    Brillanti, S.
    Andreone, P.
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (01) : 50 - 51
  • [10] Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals
    Russo, Francesco Paolo
    Zanetto, Alberto
    Campello, Elena
    Bulato, Cristiana
    Shalaby, Sarah
    Spiezia, Luca
    Gavasso, Sabrina
    Franceschet, Enrica
    Radu, Claudia
    Senzolo, Marco
    Burra, Patrizia
    Lisman, Ton
    Simioni, Paolo
    LIVER INTERNATIONAL, 2018, 38 (12) : 2210 - 2218
12345